Let's Talk: A Conversation with Dr. Charles Sawyers

Back to the list Previous article

July 21, 2025

In this webcast, Dr. Charles Sawyers, an Howard Hughes Medical Institute investigator, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the imatinib and prostate cancer resistance.

Register for the event

Key topics discussed in this webcast:

History & development of imatinib
Applying lessons learned from imatinib
Life as a physician & researcher
From GIST to metastatic castration-resistant prostate cancer
Future technology – TCEs, ADCs, TPDs

Dr. Sawyers is an Howard Hughes Medical Institute investigator and serves as the Chair of the Human Oncology and Pathogenesis Program of the Memorial Sloan Kettering Cancer Center. He co-discovered the antiandrogen drug enzalutamide approved by the FDA in 2012 for treatment of advanced prostate cancer and shared the 2009 Lasker-DeBakery Clinical Medical Research Award for the development of the ABL kinase inhibitor imatinib.

Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services.

Twitter

Facebook